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The effects of aspirin on coronary hemodynamics and 
transcardiac concentrations of thromboxane B1 (the sta-
ble metabolite of thromboxane A1) were determined at 
rest and during pacing-induced myocardial ischemia in 
11 patients with coronary disease. Control coronary si-
nus pacing increased both arterial thromboxane B1 (331 
± 70 to 623 ± 132 pg/ml, p < 0.02) and coronary sinus 
thromboxane B1 (184 ± 3 to 403 ± 156 pg/ml, p < 
0.05), but positive transmyocardial gradients developed 
in only three patients. After 650 mg of oral aspirin, more 
than 90% inhibition of in vitro thromboxline B1 pro-
duction was demonstrated and circulating thromboxane 
B1 was undetectable at rest and during pacing in all 
patients. Despite these changes in thromboxane B2 con-
centrations, coronary blood How was unchanged by as-
pirin at rest (107 ± 14 versus 112 ± 13 mlimin, p = 
NS) and during pacing (189 ± 29 versus 181 ± 25 
Several studies (1-3) suggest that patients with coronary 
artery disease may have increased thromboxane A2 produc-
tion. Although urinary excretion of prostacyclin metabolites 
may be increased in such patients (4), several studies (5-7) 
suggest that prostacyclin production at the site of diseased 
vascular endothelium may actually be diminished. Throm-
boxane A2 is a potent coronary vasoconstrictor and platelet 
activator, whereas prostacyclin is a potent coronary vaso-
dilator and platelet inhibitor (8-12). Therefore, an imbal-
ance between thromboxane A2 and prostacyclin production 
could theoretically result in coronary vasoconstriction. Cy-
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mlimin, p = NS). Myocardial lactate extraction was also 
unchanged at rest (24 ± 7 versus 19 ± 5%, P = NS) 
and during pacing (5 ± 6 versus 9 ± 5%, P = NS). 
No change occurred in the anginal threshold. 
Thus, aspirin does not have the vasoconstrictive prop-
erties that have been reported with another cyclo-
oxygenase inhibitor, indomethacin. These findings also 
suggest that thromboxane A1 production does not play 
a major role in the pathogenesis of stress-induced isch-
emilio Nonetheless, intracoronary thromboxane A1 pro-
duction in some patients may potentiate platelet acti-
vation and coronary thrombosis. Such patients may ben-
efit from long-term aspirin therapy and can be treated 
with aspirin without risk of adverse coronary hemody-
namic effects. 
(J Am Coli Cardiol 1985;5:210-5) 
clo-oxygenase inhibition could potentially remove this im-
balance and thereby improve coronary flow. However, one 
recent study (13) reported marked reductions in coronary 
blood flow in patients with coronary disease after cyclo-
oxygenase inhibition with indomethacin. This suggests that 
the maintenance of adequate coronary flow in such patients 
may be dependent on intact vascular endothelial cyclo-
oxygenase activity (14). In addition, other investigators (I5) 
have reported worsening of vasospastic angina after cyclo-
oxygenase inhibition with aspirin. The coronary hemody-
namic effects of aspirin in patients without vasospastic an-
gina are uncertain. 
Recent studies (16-18) indicate that aspirin alone or in 
combination with other agents may have beneficial effects 
in patients with unstable angina or in those who undergo 
coronary artery bypass grafting and percutaneous translu-
minal coronary angioplasty. These beneficial effects do not 
necessarily imply improvement of coronary hemodynamics 
or preclude the possibility of an adverse coronary hemo-
dynamic effect because such benefits may derive predom-
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pothesis is supported by the observation that aspirin prevented 
myocardial infarction in the Veterans Administration un-
stable angina study (16), but had no effect on the frequency 
of anginal attacks. 
Accordingly, we examined the short-term effects of 650 
mg of oral aspirin on coronary hemodynamics in patients 
with coronary artery disease. Coronary blood flow and in-
tracoronary thromboxane production were measured at rest 
and during pacing-induced myocardial ischemia. Inhibition 
of the cyclo-oxygenase enzyme complex was then docu-
mented by measuring thromboxane production in vivo and 
in vitro after aspirin administration. The effects of this in-
tervention on coronary blood flow and pacing-induced myo-
cardial ischemia were then determined. 
Methods 
Patients. Eleven patients undergoing cardiac catheter-
ization for evaluation of typical exertional angina were stud-
ied. There were 10 men and I woman ranging in age from 
39 to 76 years. All patients had greater than 75% stenosis 
of either the left anterior descending coronary artery 
(n = 2), a major branch of the left circumflex coronary 
artery (n = I) or both the left anterior descending and 
circumflex arteries (n = 8). The mean ejection fraction was 
59 ± 5%. None of the patients had received aspirin or 
aspirin-containing compounds for at least I week before the 
study. Long-acting nitrate preparations, beta-adrenergic 
blocking agents, calcium channel antagonists and dipyri-
damole were discontinued the day before the study. The 
protocol was approved by our institution's Committee for 
Studies Involving Human Subjects. Written informed con-
sent was obtained from all patients. 
Protocol. All studies were performed before angiogra-
phy and before the administration of heparin. Patients were 
brought to the cardiac catheterization laboratory in the post-
absorptive state. A coronary sinus thermodilution catheter 
(Wilton-Webster Laboratories) was advanced through thc 
right basilic vein to the mid coronary sinus. The position 
was confirmed by contrast injection and rechecked through-
out the study to assure stability. Coronary sinus flow was 
measured by the continuous thermodilution method of Ganz 
et al. (19). Arterial blood pressure was monitored with an 
A2 mUltipurpose catheter inserted percutaneously through 
the femoral artery and positioned in the abdominal aorta. 
Coronary sinus pac inN . Baseline coronary sinus flow 
was measured in duplicate, and simultaneous arterial and 
coronary sinus samples were obtained for plasma throm-
boxane B1 (the stable metabolite of thromboxane A2) and 
lactate determinations. An additional arterial blood sample 
was allowed to clot at 37°C for 15 minutes to assess in 
vitro thromboxane B2 production. Coronary sinus pacing 
was then started at a rate of 20 beats/min above the heart 
rate at rest. The pacing rate was then increased in increments 
of 20 beats/min every 2 minutes until angina occurred or a 
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heart rate of 140 beats/min was achieved. At the peak pacing 
rate, coronary sinus flow and arterial pressure were recorded 
and arterial and coronary sinus samples were again obtained 
for lactate and thromboxane B2 determinations. Pacing was 
then terminated. Additional arterial and coronary sinus sam-
ples for thromboxane B2 determinations were obtained within 
30 seconds after the discontinuation of pacing. 
Aspirin administration. Buffered aspirin (650 mg) was 
then administered orally. After 30 minutes, the entire pro-
tocol was repeated. Previous studies (20,21) have demon-
strated that aspirin administered in the postabsorptive state 
produces peak blood levels within 15 minutes. The level 
achieved with a 650 mg aspirin dose inhibits platelet and 
endothelial cyclo-oxygenase acctivity within 12 minutes 
(22-24). 
Assays. Thromboxane B2 was measured by specific ra-
dioimmunoassay. The antibody employed was obtained from 
New England Nuclear Corporation and had a low cross 
reactivity with other prostaglandins (PG): 0.2% with PGE2; 
<0.2% with PGA2, PGF2u and 6-keto PGF\u' The sensi-
tivity of the thromboxane B2 assay was 180 pg/ml. Blood 
for plasma thromboxane B2 determination was drawn in 
plastic syringes, transferred to plastic test tubes containing 
disodium (ethylenedinitrilo) tetraacetate for a final concen-
tration of 10 mM and then spun for platelet-rich plasma. 
Before high speed centrifugation to prepare platelet-poor 
plasma, indomethacin was added to give a final concentra-
tion of 10 fLM. 
To ensure that our samplinN technique did not falsely 
elevate thromboxane B2 levels, we obtained femoral venous 
blood samples in five patients by venipuncture. Immediately 
thereafter, samples were obtained from the same vessels 
first through a coronary sinus catheter and then from an 
arterial catheter. Thromboxane B2 concentrations were 
equivalent in all samples for a given patient. Other inves-
tigators (25-27) have also reported that processing blood 
drawn through indwelling catheters does not activate plate-
lets or falsely elevate thromboxane B2 levels. 
Blood.f(Jr lactate determination was deproteinized in iced 
10% perchloric acid and assayed on the same day using a 
spectrophotometric technique (28). Normal rest values in 
our laboratory are 3 to 12 mg/dl. 
Calculated values. The following values were derived 
from measured variables: 
Coronary vascular = Mean arterial pressure 
resistance Coronary sinus flow ' 
Rate-pressure ~ 
product - Heart rate x Systolic blood pressure, 
Myocardial lactate 
extraction (%) 
Arterial - Coronary sinus lactate ----------'------- x 100. 
Arterial lactate 
Normal values for myocardial lactate extraction in our lab-
oratory are 24 ± 5% at rest and 21 ± 3% during pacing. 
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Statistical methods. To calculate the mean values and 
standard errors of the mean for plasma thromboxane B2 
concentrations, values below the detectable range were ar-
bitrarily assigned a value of 180 pg/ml, as proposed by Lewy 
et al. (2). However, changes in thromboxane B2 concen-
trations were analyzed with nonparametric methods (Wil-
coxon signed rank test and Mann-Whitney test). This ap-
proach compares relative rather than absolute values, so it 
does not require assignment of an arbitrary value for con-
centrations below the detectable range. Changes in other 
variables were assessed with the t test for paired or unpaired 
data as appropriate. A probability (p) value of less than 0.05 
was considered significant. All values are expressed as mean 
± standard error of the mean. 
Results 
Thromboxane B2 concentrations. Pacing was accom-
panied by typical angina, ischemic electrocardiographic 
Figure I. Effect of pacing on arterial (Ao) and coronary sinus 
(CS) thromboxane B2 before (pre) and after (post) aspirin (ASA). 
Pacing was associated with significant increases in both arterial 
and coronary sinus thromboxane B2 concentrations. All arterial 
and coronary sinus thromboxane B2 concentrations were unde-
tectable « 180 pg/ml) after aspirin. 
1000 .-------~---------r--------,_--------, 
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changes or abnormal myocardial lactate metabolism. alone 
or in combination, in all patients. Changes in plasma throm-
boxane B2 concentrations during this pacing stress are sum-
marized in Figure 1. The basal arterial thromboxane B2 
concentration was 331 ± 70 pg/ml, which increased to 529 
± 189 pg/ml during pacing (p = 0.1 versus baseline). 
Immediately after pacing, the concentration increased fur-
ther to 623 ± 132 pg/ml (p < 0.02 versus baseline). All 
patients had an arterial thromboxane B2 concentration that 
was in the detectable range of our assay (> 180 pg/ml) during 
and after pacing. 
The basal coronary sinus thromboxane B2 concentration 
was 184 ± 3 pg/ml, which increased to 403 ± 156 pg/ml 
during pacing (p < 0.05). Immediately after pacing, the 
coronary sinus thromboxane B2 concentration increased fur-
ther to 504 ± 194 pg/ml (p = 0.06 versus baseline). Three 
patients developed a positive trans myocardial thromboxane 
B2 coronary gradient during or after pacing, suggesting in-
tracoronary thromboxane A2 production. These gradients 
ranged from 180 to 1 ,400 pg/ml. Because arterial throm-
boxane B2 concentrations were in the detectable range of 
our assay in all patients during and after pacing, additional 
small gradients could not have been missed because of the 
assay sensitivity. 
After aspirin, thromboxane B2 was undetectable in all 
arterial and coronary sinus plasma samples. In vitro, throm-
boxane B2 production in blood incubated at 37°C was also 
reduced in all patients from more than 15,000 to 1,250 ± 
83 pg/ml (p < 0.001). 
Coronary hemodynamics. Changes in coronary blood 
flow and coronary vascular resistance during pacing are 
summarized in Figure 2. The rate-pressure product was 9,100 
± 500 at rest, which increased to 18,200 ± 900 with 
pacing. This was associated with an increase in coronary 
sinus blood flow from 107 ± 14 to 189 ± 29 mllmin and 
a decrease in coronary vascular resistance from 1. 16 ± 
0.50 to 0.75 ± 0.12 mm Hg.ml·min - I. 
After aspirin, the rate-pressure products at rest (9,800 
± 500) and at peak pacing (18,300 ± 900) were compa-
rable with values noted before aspirin. Coronary sinus blood 
flows at rest (112 ± 13 mllmin) and peak pacing (181 ± 
25 mllmin) were also comparable with values before aspirin. 
as were coronary vascular resistance values at rest (1. 13 ± 
0.06 mm Hg·ml·min- I ) and at peak pacing (0.78 ± 0.40 
mm Hg·ml·min -I). The subgroup of patients with positive 
transmyocardial thromboxane B2 gradients during pacing 
also had no change in coronary blood flow or coronary 
vascular resistance after aspirin. 
Lactate metabolism and anginal threshold. Changes 
in myocardial lactate extraction during pacing are illustrated 
in Figure 3. During pacing, myocardial lactate extraction 
decreased from 24 ± 7 to 5 ± 6% (p < 0.05), with six 
patients demonstrating zero or negative lactate extraction. 
Seven patients developed ischemic electrocardiographic 
changes during pacing and nine patients experienced typical 
000 ,- --r -r- ,--- --
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Figure 2. Coronary blood flow and coronary vascular resistance 
(mm Hg·min·ml- I ) relative to the rate-pressure (double) product 
at rest and during pacing. The rate-pressure products were equiv-
alent before (pre) and after (post) aspirin (ASA). Coronary blood 
flow and coronary vascular resistance were not significantly altered 
by aspirin. 
angina. After aspirin, myocardial lactate extraction at rest 
(19 ± 5%) and at peak pacing (9 ± 5%) were not signif-
icantly different from values before aspirin and ischemic 
electrocardiographic responses were also unchanged. Eight 
of 11 patients developed typical angina during pacing after 
aspirin (p = NS versus before aspirin). 
Discussion 
In a previous study (1), we reported that arterial throm-
boxane B2 concentrations increase during pacing-induced 
myocardial ischemia, but that detectable intracoronary 
thromboxane B2 production occurs in a minority of patients. 
The present study confirms these observations in a series of 
patients with stable exertional angina. Other investigators 
(29-31) have reported similar findings in patients with stable 
coronary artery disease. Whether the changes in the con-
centrations of thromboxanes noted during pacing have an 
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Figure 3. Myocardial lactate extraction relative to the rate-
pressure (double) product at rest and during pacing. The rate-
pressure products were equivalent before (pre) and after (post) 
aspirin (ASA). Myocardial lactate extraction was not significantly 
altered by aspirin. 
adverse effect on coronary flow is I./ncertain. Moreover, 
it is possible that more marked regional throrqboxane pro-
duction occurs in some coronary vascular beds but goes 
undetected in the overall coron~ry sinus drainage. 
Effects of aspirin on corQnary flow and resistance. To 
further evaluate the role of thromboxane A2 in the patho-
genesis of stress-induced myocardial ischemia, its produc-
tion was inhibited with aspirin in the present study. After 
the administration of aspirin, thromboxane B2 was unde-
tectable in the arterial ~nd coronary sinus blood flow of all 
patients. Despite these alterations in thromboxane B2 con-
centrations, aspirin did not significantly alter coronary flow 
or coronary vascular resistance, even in patients who had 
positive transmyocardial thromboxane B2 gradients before 
aspirin. In addition, aspirin did not appear to enhance nu-
tritive flow to the myocardium since lactate production, the 
anginal threshold and ischemic electrocardiographic changes 
were not altered during pacing. This suggests that throm-
boxane A2 production does not play a major role in the 
pathogenesis of stress-induced myocardial ischemia. These 
results are consistent with those from previous studies (32,33) 
which found that aspirin did rot affect the anginal threshold 
during treadmill exercise in patients with coronary disease. 
These findings, however, do not exclude the possibility that 
in other circumstances, more substantial intracoronary 
thromboxane production may have a more marked effect on 
coronary hemodynamics. In addition, the intracoronary pro-
duction of thromboxanes noted in some patients may be 
important as a potential mediator of intracoronary platelet 
aggregation and coronary thrombosis. 
Role of inhibition of prostacyclin production. It is 
possible that potential beneficial coronary hemodynamic ef-
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study because of concomitant inhibition of prostacycIin pro-
duction. Platelets appear to be more sensitive than the vas-
cular endothelium to cycIo-oxygenase inhibition with low 
dose aspirin (34-36). However, the higher dose of aspirin 
used in the present study would be expected to cause sub-
stantial suppression of vascular endothelial prostacycIin pro-
duction (23,24,34,35). Prior studies also indicate that this 
dose of aspirin results in peak plasma levels in excess of 
100 IJ.M within 15 minutes (20,21) and that such concen-
trations inhibit vascular endothelial prostacycIin production 
in vivo and in vitro within 12 minutes (23,24). Thus, lower 
doses of aspirin or selective inhibitors of thromboxane A2 
synthetase might have a different effect on coronary flow. 
However, another preliminary study (31) noted no signifi-
cant change in the anginal threshold after the administration 
of a specific thromboxane A2 inhibitor which does not de-
crease prostacyclin production. 
Comparison with indomethacin. Our hemodynamic 
findings also indicate that cycIo-oxygenase inhibition with 
650 mg of aspirin did not have an immediate adverse effect 
on coronary flow. In contrast, Friedman et al. (13) reported 
a decrease in coronary sinus flow at rest after cycIo-
oxygenase inhibition with intravenous indomethacin. The 
explanation for these differing results is not certain. It is 
possible that indomethacin causes more complete inhibition 
of vascular endothelial cycIo-oxygenase activity. However, 
cycIo-oxygenase activity was not assessed in the study of 
Friedman et al. Alternatively, it is possible that the reduction 
in coronary blood flow noted with indomethacin is a direct 
drug effect and not related to cycIo-oxygenase inhibition. 
This alternative is supported by the finding that indometh-
acin causes vasoconstriction in animals, whereas another 
cyclo-oxygenase inhibitor, ibuprofen, has no adverse hemo-
dynamic effect (37). 
Potential limitations. ldeaIly, we would have quanti-
tated the effect of aspirin on pacing-induced intracoronary 
prostacycIin production. Currently there is uncertainty about 
the specificity of radioimmunoassay measurements of plasma 
6-keto PGF"o a stable prostacyclin metabolite. It is believed 
that antibodies to 6-keto PGF,u may cross react with other 
prostanoids (38,39). This compound can be measured by 
high performance liquid chromatography or gas chroma-
tography mass spectrometry (38,39). However, such tech-
niques require substantially larger blood samples than can 
be drawn safely from the coronary sinus during repeated 
episodes of pacing-induced myocardial ischemia. Thus, we 
documented cycIo-oxygenase inhibition by measuring in vivo 
and in vitro thromboxane B2 production. Preliminary work 
in our laboratory also indicates more than 80% reduction in 
the transmyocardial gradient of 6-keto PGF 'n immunoreac-
tivity with the dose of aspirin employed in the present study. 
It is likely that other prostanoids are reflected in part in this 
gradient. Nonetheless, such a reduction is additional sup-
portive evidence that coronary vascular cycIo-oxygenase 
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activity was indeed inhibited, as had been expected from 
the findings of prior studies (23,24,34,35). 
Conclusions. CycIo-oxygenase inhibition with 650 mg 
of aspirin does not alter hemodynamics during rapid atrial 
pacing. Thus, aspirin does not have the vasoconstrictive 
properties that have been reported with another cycIo-
oxygenase inhibitor, indomethacin. These data also suggest 
that thromboxane A2 production does not playa major role 
in the pathogenesis of stress-induced ischemia. Nonetheless, 
intracoronary thromboxane A2 production in some patients 
could potentiate platelet activation and coronary thrombosis. 
Such patients may benefit from long-term aspirin therapy 
and can be treated with aspirin without risk of adverse coro-
nary hemodynamic effects. 
We thank Nancy L. Shade and Kathleen A. Cioschi for the preparation of 
this manuscript. and the technical and nursing staff of the cardiac cathe-
terization laboratory for their continued support. 
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